Source: Healio Coverage
February 18, 2021
1 min read
Save

Top in hem/onc: MRI vs. PSA screening, COVID-19’s effect on cancer diagnoses

Source: Healio Coverage
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A new study suggests that MRI testing could be used to detect prostate cancer. It was the top story in hematology/oncology last week.

Another top story revealed that the number of cancer screenings dropped considerably during the peak of the COVID-19 pandemic. However, in the first 3 months after the initial peak, researchers said there was a “near-complete” rebound in the number of cancer screenings.

MRI
Source: Adobe Stock

Read these and more top stories in hematology/oncology below:

‘Fast’ MRI shows potential as prostate cancer screening method

MRI testing improved the detection of clinically significant prostate cancer without increasing overdiagnoses compared with PSA testing, according to a prospective, population-based, blinded cohort study published in JAMA Oncology. Read more.

Data confirm decline in cancer screenings, diagnoses amid first peak of COVID-19 pandemic

Substantial decreases in cancer screenings and diagnoses occurred during the first peak of the COVID-19 pandemic across one large U.S. health care system, according to a research letter published in JAMA Oncology. Read more.

Interventions may reduce patient distress during bone marrow biopsy

Patients undergoing bone marrow biopsy would respond favorably to interventions intended to improve their experience, according to study results presented at TCT Meetings Digital Experience. Read more.

FDA approves Libtayo for advanced basal cell carcinoma

The FDA granted regular approval to Libtayo (cemiplimab-rwlc; Regeneron Pharmaceuticals, Sanofi Genzyme) for patients with locally advanced basal cell carcinoma who were previously treated with or ineligible for treatment with a hedgehog pathway inhibitor. Read more.

FDA panel: Defer decision on pembrolizumab for early-stage triple-negative breast cancer

An FDA advisory committee voted unanimously to recommend deferral of a regulatory decision on Keytruda (pembrolizumab; Merck) for the treatment of patients with high-risk, early-stage triple-negative breast cancer. Read more.